India seizes $41 billion Russian pharma opportunity

9 June 2025

The Russian pharmaceutical market, valued at around $41 billion, continues to be a magnet for Indian pharmaceutical companies.

While geopolitical shifts and Western sanctions have created a significant vacuum, the doors have been thrown open for Indian players, and the veritable red carpet rolled out, as Russia turns to India to establish production facilities and enhance pharmaceutical exports, reports The Pharma Letter’s India correspondent.

The Russian Direct Investment Fund (RDIF) is eager to provide financial support and is actively supporting joint ventures in India. RDIF has partnered with several Indian companies to facilitate investment and production expansion, said an official.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK